Patent application number | Description | Published |
20130179149 | COMMUNICATION PROCESSING - Disclosed are methods and apparatus for processing linguistic expressions (e.g., opinionated text documents). The linguistic expressions are processed by, firstly, detecting topics of interest discussed in the linguistic expressions. The sentiment, or sentiments, of an originator with respect to each of the topics detected in the linguistic expressions is then assessed. The originators are then grouped (or clustered) into one or more groups based on the similarities between the originators' respective sets of detected topics and corresponding sentiments. Semantic information is then associated with a given group. Finally, for a given member of a given group, a profile is created or updated. This profile comprises attributes that may be based on a degree of membership of the given member to the given group and the semantic information associated with the given group. | 07-11-2013 |
20140089967 | PROVIDING SECONDARY CONTENT TO ACCOMPANY A PRIMARY CONTENT ITEM - While a user views a primary content item (for example, a movie on a television screen), secondary content items are selected and presented to the user, either on the same screen or on a screen of the user's companion device. To choose selections that are relevant to the user's current interests, the selection process considers information beyond the realm of primary and secondary content. Over time, the selection process learns to make more relevant selections by monitoring selection choices made by other systems. | 03-27-2014 |
20140258204 | INFERRING ATTRIBUTE AND ITEM PREFERENCES - User-preference datapoints are collected. At least some of these datapoints are associated with user-preference information about an item (e.g., a movie), and some of these datapoints are associated with user-preference information about an attribute (e.g., a movie genre or an actor). A profile of the user is created based, at least in part, on these datapoints. When a new datapoint is collected, the new datapoint is assigned a user-preference “score.” If, for example, the new datapoint does not come with an explicit user-preference rating, then the score is based on related item and attribute datapoints already in the profile. Depending upon the relationship of the new datapoint to the already existing datapoints, a confidence value is assigned to the user-preference score. The profile is then updated with the new datapoint along with its assigned score and confidence rating. The user profile can be used in performing any number of actions. | 09-11-2014 |
20140266782 | CONTEXT HEALTH DETERMINATION SYSTEM - Systems, methods, and devices for determining contexts and determining associated health profiles using information received from multiple health sensor enabled electronic devices, are disclosed. Contexts can be defined by a description of spatial and/or temporal components. Such contexts can be arbitrarily defined using semantically meaningful and absolute descriptions of time and location. Health sensor data is associated with or includes context data that describes the circumstances under which the data was determined. The health sensor data can include health sensor readings that are implicit indications of health for the context. The sensor data can also include user reported data with explicit descriptions of health for the context. The health sensor data can be filtered by context data according a selected context. The filtered sensor data can then be analyzed to determine a health profile for the context that can be output to one or more users or entities. | 09-18-2014 |
20140280138 | CONTEXT DEMOGRAPHIC DETERMINATION SYSTEM - Systems, methods, and devices for determining contexts and determining associated demographic profiles using information received from multiple demographic sensor enabled electronic devices, are disclosed. Contexts can be defined by a description of spatial and/or temporal components. Such contexts can be arbitrarily defined using semantically meaningful and absolute descriptions of time and location. Demographic sensor data is associated with or includes context data that describes the circumstances under which the data was determined. The demographic sensor data can include demographic sensor readings that are implicit indications of a demographic for the context. The sensor data can also include user reported data with explicit descriptions of a demographic for the context. The demographic sensor data can be filtered by context data according a selected context. The filtered sensor data can then be analyzed to determine a demographic profile for the context that can be output to one or more users or entities. | 09-18-2014 |
20140280529 | CONTEXT EMOTION DETERMINATION SYSTEM - Systems, methods, and devices for determining contexts and determining associated emotion profiles using information received from multiple emotion sensor enabled electronic devices, are disclosed. Contexts can be defined by a description of spatial and/or temporal components. Such contexts can be arbitrarily defined using semantically meaningful and absolute descriptions of times and locations. Emotion sensor data is associated with or includes context data that describes the circumstances under which the data was determined. The emotion sensor data can include emotion sensor readings that are implicit indications of an emotion for the context. The sensor data can also include user reported data with explicit descriptors of an emotion for the context. The emotion sensor data can be filtered by context data according a selected context. The filtered sensor data can then be analyzed to determine an emotion profile for the context that can be output to one or more users or entities. | 09-18-2014 |
Patent application number | Description | Published |
20090325193 | Diagnostic Test For The Detection Of A Molecule Or Drug In Whole Blood - The invention provides methods of preparing a test sample for use in an assay for detecting an analyte bound by an intracellular ligand. The methods typically involve contacting the test sample with an assay reagent comprising: a lysis reagent; and a protease that has proteolytic activity for said intracellular ligand; to form a mixture compatible for use in an immunoassay without subsequent extraction steps. Other aspects of the invention include related immunoassays and test kits. | 12-31-2009 |
20100116662 | NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (NGAL) PROTEIN ISOFORMS ENRICHED FROM URINE AND RECOMBINANT CHINESE HAMSTER OVARY (CHO) CELLS AND RELATED COMPOSITIONS, ANTIBODIES, AND METHODS OF ENRICHMENT, ANALYSIS AND USE - A composition comprising neutrophil gelatinase-associated lipocalin (NGAL), which has been enriched from urine, has a molecular weight of about 24.9 kDa to about 25.9 kDa, and comprises a plurality of isoforms having isoelectric points (pIs) ranging from about 5.9 to about 9.1; a composition comprising NGAL, which has been enriched from recombinant Chinese hamster ovary (CHO) cells, has a molecular weight of about 25.9 kDa to about 27.9 kDa, and comprises a plurality of isoforms having pIs ranging from about 5.6 to about 9.1; a method of obtaining from urine a composition comprising a plurality of isoforms of NGAL, which method comprises enriching NGAL in urine without separating molecules based on charge; a method of obtaining from recombinant CHO cells a composition comprising a plurality of isoforms of NGAL, which method comprises enriching NGAL in a composition without separating molecules based on charge; and a method of analyzing NGAL isoforms enriched from urine or recombinant CHO cells comprising analyzing an enriched composition comprising NGAL isoforms by two-dimensional electrophoresis and Western blot. | 05-13-2010 |
20110008766 | Dual Variable Domain Immunoglobulins and Uses Thereof - Engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 01-13-2011 |
20110091997 | IMMUNOSUPPRESSANT DRUG EXTRACTION REAGENT FOR IMMUNOASSAYS - An improved extractive reagent composition and method for extracting an immunosuppressant drug, such as sirolimus, tacrolimus or cyclosporine, from blood samples while yielding a test sample extract that has low vapor pressure and is compatible with immunoassay components. The inventive reagent composition comprises dimethyl sulfoxide (DMSO), at least one divalent metal salt and water. The sample extracts resulting from use of each of these combinations have low vapor pressure and are compatible with immunochemistry assays. | 04-21-2011 |
20110171662 | NON-DENATURING LYSIS REAGENT - The invention provides a lysis reagent and method for preparing a test sample for use in an assay, wherein the method yields a homogeneous lysis mixture suitable for use in automated pipetting systems without the need for a centrifugation step. The lysis reagent includes a glycol and an alcohol. Other aspects of the invention include related immunoassays and test kits. | 07-14-2011 |
20120288875 | Diagnostic Test For The Detection Of A Molecule Or Drug In Whole Blood - The invention provides methods of preparing a test sample for use in an assay for detecting an analyte bound by an intracellular ligand. The methods typically involve contacting the test sample with an assay reagent comprising: a lysis reagent; and a protease that has proteolytic activity for said intracellular ligand; to form a mixture compatible for use in an immunoassay without subsequent extraction steps. Other aspects of the invention include related immunoassays and test kits. | 11-15-2012 |
Patent application number | Description | Published |
20080286351 | Pegylated Cardiolipin Analogs, Methods of Synthesis, and Uses Thereof - The invention provides synthetic methods for PEGylated cardiolipins with varying linkers. The methods can be employed to prepare PEGylated cardiolipin with different fatty acid and/or alkyl chain length with or without unsaturation. The PEGylated cardiolipin, prepared by the present methods, can be incorporated into liposomes that can also include active agents such as hydrophilic or hydrophobic drugs for the treatment of human and animal diseases. In addition, the PEGylated cardiolipin can be incorporated into liposomes that include compounds for therapeutic and diagnostic imaging. The use of such liposomes with PEGylated cardiolipin prolongs the period of liposomal circulation without disrupting the lipid bilayer. | 11-20-2008 |
20100068251 | Aqueous Systems For The Preparation Of Lipid Based Pharmaceutical Compounds; Compositions, Methods, And Uses Thereof - The present invention relates to a methods of preparing active compounds complexed with lipids using aqueous systems that are free of organic solvents, and methods of using the complexes, e.g., in treating a disease in a subject. In some embodiments, the present invention comprises a composition comprising a complex comprising at least one active compound, e.g., a polyene antibiotic, an immunosuppressant agent such as tacrolimus or a taxane or taxane derivative, and one or more lipids. In some embodiments, the present invention provides a method comprising preparing a composition comprising a lipid complex comprising at least one active compound and at least one lipid and administering the composition to a subject. In certain embodiments the subject is a mammal. In certain preferred embodiments, the subject is human. | 03-18-2010 |
Patent application number | Description | Published |
20090291134 | ENDOXIFEN METHODS AND COMPOSITIONS IN THE TREATMENT OF PSYCHIATRIC AND NEURODEGENERATIVE DISEASES - The present invention provides compositions containing endoxifen, formulations and liposomes of endoxifen, methods of preparation of such agents and formulations, and use of such agents and formulations for the treatment of a subject having or at risk for psychiatric and neurodegenerative diseases. Specifically, the present invention relates to the composition comprising endoxifen in the treatment of bipolar disorder, schizophrenia, multiple sclerosis (MS), Alzheimer disease, Parkinson disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), and/or epilepsy by administrating formulations or compositions comprising an effective amount of endoxifen. | 11-26-2009 |
20100112041 | Endoxifen Compositions And Methods - The present invention provides compositions containing endoxifen, formulations and liposomes of endoxifen, methods of preparation of such agents and formulations, and use of such agents and formulations for the treatment of breast cancer and other breast diseases and diseases susceptible to endoxifen. In particular, the compositions of the present invention include liposomes, complexes, vesicles, emulsions, micelles and mixed micelles of endoxifen in which the compositions further contain any of a variety of neutral or charged lipids and desirably, cholesterol and cholesterol derivatives, sterols, Z- and E-guggulsterones, phospholipids, fatty acids, vitamin D, and vitamin E. The present invention also provides methods of preparing endoxifen. The present invention provides methods for treating and preventing breast cancer and other breast related diseases by administrating novel formulations or compositions comprising a therapeutically effective amount of endoxifen. | 05-06-2010 |
20100151002 | Guggulphospholipid Methods and Compositions - The present invention relates to the methods for preparing synthetic guggulphospholipids, their fatty acid analogues and other bioactive molecules. The present invention relates to E-guggulsterone and Z-guggulsterone or mixture of E- and Z-guggulsterones. The present invention also provides a novel method for the preparation of E-guggulsterol and Z-guggulsterol or mixture of E- and Z-guggulsterols from a mixture of E- and Z-guggulsterones. The present invention further relates to guggulphospholipids and other bioactive molecules incorporated into complexes such as liposomes, complexes, emulsions, vesicles, micelles, and mixed micelles, which can include other active agents, such as hydrophobic or hydrophilic drugs for use, e.g., in treatment of human and animal diseases. | 06-17-2010 |
20100323000 | METHOD AND PROCESS FOR PREPARING CARDIOLIPIN - The invention provides novel methods for preparing cardiolipin and cardiolipin analogs having varying fatty acid chain lengths, particularly 1,1′,2,2′-tetramyristoyl cardiolipin. The methods comprise reacting a starting compound, such as a 1,2-O-sn-diacylglycerol and a 2-protected glycerol, with a phosphoramidite reagent to produce a protected cardiolipin, which is deprotected to prepare cardiolipin. The cardiolipin and cardiolipin analogs may be prepared in the presence of an activator, such as pyridinium trifluororacetate. The methods of the present invention are used to prepare cardiolipin and cardiolipin analogs in large quantities. The cardiolipin prepared by the present methods can be incorporated into liposomes which can also include active agents such as hydrophobic or hydrophilic drugs. Such liposomes can be used to treat diseases or in diagnostic and/or analytical assays. | 12-23-2010 |
20120164075 | ENDOXIFEN METHODS AND COMPOSITIONS IN THE TREATMENT OF MAMMALIAN DISEASES - The present invention provides compositions containing endoxifen, formulations and liposomes of endoxifen, methods of preparation of such agents and formulations, and use of such agents and formulations for the treatment of a subject having or at risk for psychiatric and neurodegenerative diseases, infectious diseases, fertility disorders, osteoporosis, osteoarthritis, and/or cardiovascular diseases. Specifically, the present invention relates to compositions comprising endoxifen for use in the treatment of such disorders or predisposition to such disorders, for use in manufacture of medicaments for treating such disorders, and methods comprising use of such compositions in such treatments. | 06-28-2012 |
Patent application number | Description | Published |
20100014941 | APPARATUS AND METHOD OF MAKING A HEEL-LESS NAIL - A full-round head nail having an offset head is configured with a gusset formed integrally between an undersurface of the offset head and a superior portion of a shank. The head of the nail is relatively thin, and the shank is positioned radially off center of the round head such that no heel is formed at a point tangential to both the head and the shank. The gusset has a lofted surface tapering radially from a roundness at the zero heel to a taper at the toe. The gusset reinforces the junction of the shank with the head, supports the toe of the head, and distributes the force of a load on the head through a longitudinal axis of the shank, preventing the toe from bending or yielding and prevents the shank from yielding to the stresses of the load applied. | 01-21-2010 |
20100183403 | APPARATUS AND METHOD OF MAKING AN OFFSET NAIL - A nail having an offset head is configured with a multi-step support gusset formed integrally between an undersurface of the offset head and a superior portion of a shank. The head of the nail is relatively thin, and the shank is positioned radially off center of the head. A first portion of the gusset defines an angle relative to the shank axis and the second portion of the gusset defines an angle relative to the shank axis different from that of the first portion. The support gusset reinforces the junction of the shank with the head, supports the toe of the head, and distributes the force of a load on the head through a longitudinal axis of the shank, preventing the toe from bending or yielding and prevents the shank from yielding to the stresses of the load applied. | 07-22-2010 |
20110098122 | APPARATUS AND METHOD OF MAKING A HEEL-LESS NAIL - A full-round head nail having an offset head is configured with a gusset formed integrally between an undersurface of the offset head and a superior portion of a shank. The head of the nail is relatively thin, and the shank is positioned radially off center of the round head such that no heel is formed at a point tangential to both the head and the shank. The gusset has a lofted surface tapering radially from a roundness at the zero heel to a taper at the toe. The gusset reinforces the junction of the shank with the head, supports the toe of the head, and distributes the force of a load on the head through a longitudinal axis of the shank, preventing the toe from bending or yielding and prevents the shank from yielding to the stresses of the load applied. | 04-28-2011 |
20110098123 | APPARATUS AND METHOD OF MAKING A HEEL-LESS NAIL - A full-round head nail having an offset head is configured with a gusset formed integrally between an undersurface of the offset head and a superior portion of a shank. The head of the nail is relatively thin, and the shank is positioned radially off center of the round head such that no heel is formed at a point tangential to both the head and the shank. The gusset has a lofted surface tapering radially from a roundness at the zero heel to a taper at the toe. The gusset reinforces the junction of the shank with the head, supports the toe of the head, and distributes the force of a load on the head through a longitudinal axis of the shank, preventing the toe from bending or yielding and prevents the shank from yielding to the stresses of the load applied. | 04-28-2011 |
Patent application number | Description | Published |
20100129497 | USE OF NOVEL CARBOHYDRATES AND CARBOHYDRATE BLENDS TO PROVIDE A SPORTS BEVERAGE WITH INCREASED ABSORPTION - A carbohydrate blend is provided, including at least fructose and glucose. Some or all of the glucose may be provided by glucooligosaccharides having a structure containing up to ten degrees of saccharide polymerization. An aqueous solution having 6% by weight of the carbohydrate blend has a measured osmolality of 230-300 mOsm/kg. Further, the measured osmolality of the carbohydrate solution is substantially stable during storage for up to six months. Also, a rehydration/sports beverage composition is provided, including water, a carbohydrate blend, electrolytes, and optionally edible acids, coloring agents, flavoring agents and the like. The beverage composition may have a measured osmolality of about 230-260 mOsm/kg, which provides faster absorption by the gastrointestinal system of a subject than a beverage composition with a higher osmolality. | 05-27-2010 |
20110034548 | Method for Suspending a Flavonoid in a Beverage - Disclosed is a method for suspending microparticulated flavonoid in a beverage by incorporating a microparticulated flavonoid and at least one suspension agent into a beverage. A composition comprising microparticulated quercetin and a suspension agent is also disclosed. | 02-10-2011 |
20110151059 | PROTEIN RECOVERY BEVERAGE - A protein rehydration/recovery beverage composition is provided, including an aqueous component such as water, hydrolyzed protein, and sodium acid sulfate and at least one other edible acid. The hydrolyzed protein may be hydrolyzed whey and optionally hydrolyzed collagen. In addition, the beverage composition may include at least one carbohydrate, such as sucrose, and one or more non-nutritive sweeteners. A protein rehydration/recovery beverage composition is provided, including an aqueous component, hydrolyzed proteins and an acid blend. The acid blend contains a first acid component including at least one of phosphoric acid and citric acid, and a second acid component including at least one of tartaric acid, fumaric acid, malic acid, gluconic acid, ascorbic acid, and lactic acid. Also, a method for making a protein recovery beverage composition that has a pH of less than about 4.2. The rehydration/recovery beverage is stable and clean tasting, and has a low viscosity. | 06-23-2011 |
20110300266 | ELECTROLYTE BLENDS PROVIDING REDUCED SALTY TASTE - An electrolyte blend is provided having a minimal salty taste in water or other rehydration compositions. One electrolyte blend includes sodium lactate and potassium chloride. An alternate electrolyte blend includes sodium lactate, potassium gluconate, and calcium chloride. The electrolyte blend may be provided as a beverage product, for example a rehydration product containing carbohydrates. In addition, a rehydration beverage composition is provided including water, at least one sweetener, at least one acid, and an electrolyte blend including sodium chloride, sodium lactate, and at least one of potassium chloride, potassium citrate and monopotassium phosphate. An alternate beverage composition is provided including water, at least one sweetener, at least one acid, and an electrolyte blend including sodium chloride, magnesium oxide, calcium lactate, and at least one of potassium chloride, potassium citrate, monopotassium phosphate, sodium lactate and calcium chloride. | 12-08-2011 |